Compare IZM & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZM | XRTX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.3M |
| IPO Year | 2021 | 2018 |
| Metric | IZM | XRTX |
|---|---|---|
| Price | $0.26 | $2.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 211.9K | 13.3K |
| Earning Date | 10-24-2025 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.35 |
| 52 Week High | $2.73 | $3.60 |
| Indicator | IZM | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 57.19 |
| Support Level | $0.24 | $2.00 |
| Resistance Level | $0.30 | $2.24 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 38.27 | 81.25 |
ICZOOM Group Inc. operates an e-commerce platform selling electronic components to SMEs in China across consumer electronics, IoT, automotive, and industrial control sectors. It offers two main product categories: semiconductor products, including integrated circuits and optoelectronics, and electronic equipment and tools such as electromechanical and MRO supplies. The company also provides services like customs clearance, temporary warehousing, and logistics, earning additional commission fees. The majority of its revenue comes from electronic component sales.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.